This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAP4K5 / Mitogen-activated protein kinase kinase kinase kinase 5 · IHC design guide
Design Immunohistochemistry for MAP4K5
Plan MAP4K5 staining in paraffin sections around the reported cytoplasmic tissue pattern, while accounting for its uncertain reliability (HPA tissue IHC). This guide covers tissue controls, fixation consistency and the catalog antibody’s IHC range of 2–5 µg/mL (datasheet A10186-1).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MAP4K5 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in a subset of tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining, mainly in smooth muscle (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A10186-1) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining has uncertain reliability and low RNA concordance (HPA tissue IHC) | |
| Regulation | Higher in ovary, testis and prostate (UniProt) | |
| Isoform / epitope | No listed isoforms; one unprocessed chain (UniProt) |
Section 1
Recommended MAP4K5 IHC & IF Protocols
The catalog antibody protocol uses EDTA pH 8.0 heat retrieval (datasheet A10186-1). The published pancreatic tissue protocol below reports a steamer-based IHC workflow (PMC4811546).
| Sample | Paraffin-embedded human ovarian cancer tissue; fixative not specified (datasheet A10186-1) |
| Fixation | Image fixative and duration unreported (datasheet A10186-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A10186-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A10186-1) |
| Primary antibody | Rabbit anti-MAP4K5, 2μg/ml (datasheet A10186-1) |
| Primary incubation | Overnight at 4 °C (datasheet A10186-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A10186-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MAP4K5-positive staining in purkinje cells of cerebellum (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in a subset of tissues, mainly smooth muscle. No signal in the no-primary control. |
💡Decision noteTry EDTA pH 8.0 heat retrieval first (datasheet A10186-1); the published steamer treatment does not specify a buffer (PMC4811546).
Section 2
What Is the Expected MAP4K5 Staining Pattern?
MAP4K5 is a cytoplasmic protein with no transmembrane segment (UniProt Q9Y4K4: subcellular location and topology). In paraffin section IHC, expect cytoplasmic staining in selected cells; HPA describes a subset of tissues, mainly smooth muscle, and reports medium staining in several named cell populations (HPA: tissue IHC). Treat these as provisional reference patterns: HPA rates tissue IHC reliability Uncertain because antibody staining and RNA expression show low consistency (HPA: tissue IHC reliability).
| Cytoplasmic staining in smooth muscle or in HPA-listed cells, such as ovarian follicle cells or cerebellar Purkinje cells (HPA: tissue IHC). | This fits the reported compartment and cell distribution (UniProt Q9Y4K4: cytoplasm; HPA: tissue IHC). HPA scores the listed follicle and Purkinje cells Medium, but its tissue IHC reliability is Uncertain (HPA: tissue IHC). |
| Predominantly nuclear staining, or a sharp membrane-only outline, with little cytoplasmic signal. | That conflicts with the reported cytoplasmic IHC profile and UniProt location (HPA: tissue IHC; UniProt Q9Y4K4: cytoplasm). Review controls and imaging before assigning MAP4K5; membrane localization in ICC-IF is itself uncertain (HPA: subcellular). |
| Strong staining in cells HPA reports as not detected, such as adipocytes or cardiomyocytes (HPA: tissue IHC). | Investigate antibody cross-reactivity or endogenous detection activity (standard IHC practice). A discordant cell type is a warning, not proof of either mechanism; HPA's tissue IHC assessment is Uncertain (HPA: tissue IHC reliability). |
| Diffuse colour across many cell types, including areas expected to be unstained. | A widespread haze can obscure cell boundaries and make compartment scoring unreliable (standard IHC practice). Assess a no-primary control and compare staining with HPA's selective cytoplasmic tissue profile (standard IHC practice; HPA: tissue IHC). |
| No cytoplasmic signal in an HPA-listed medium-staining population, such as colon endothelial cells (HPA: tissue IHC). | First check tissue identity, preservation, retrieval, primary incubation and detection controls (standard IHC practice). HPA's Medium rating is an observed pattern, not a guarantee that every section or antibody will stain (HPA: tissue IHC reliability Uncertain). |
💡Expected MAP4K5 appearanceCall a result plausible when staining is chiefly cytoplasmic in an appropriate cell population at a discernible, approximately medium level; isolated nuclear signal, membrane-only outlines or broad staining of HPA-negative cells warrant control review (UniProt Q9Y4K4: cytoplasm; HPA: tissue IHC and reliability; standard IHC practice).
| Location and topology | UniProt places MAP4K5 in the cytoplasm and lists no transmembrane segment (UniProt Q9Y4K4: location and topology). Judge chromogenic IHC primarily by cytoplasmic cell staining; do not require a membrane outline to call a positive result (HPA: tissue IHC; standard IHC practice). |
| Tissue and cell selection | HPA reports cytoplasmic staining mainly in smooth muscle and Medium staining in selected cells, including duodenal glandular cells and skeletal myocytes (HPA: tissue IHC). Select controls by the scored cell population within the section, rather than by tissue name alone (standard IHC practice). |
| Expression versus observed staining | UniProt describes expression throughout examined tissues, with higher levels in ovary, testis and prostate (UniProt Q9Y4K4: tissue specificity). HPA reports only a subset of tissues staining and low tissue RNA specificity (HPA: tissue IHC). Do not infer an IHC positive solely from expression information (standard IHC practice). |
| Strength of IHC evidence | HPA calls tissue IHC Uncertain for low antibody-staining and RNA-expression consistency; HPA036696 is also rated Uncertain for IHC (HPA: tissue IHC reliability; HPA: antibody validation). Interpret a new pattern alongside controls rather than treating the reference image as definitive (standard IHC practice). |
| IF/ICC Q: should a membrane or ciliary signal count? | A: HPA supports cytosol as the main ICC-IF location; plasma membrane and primary cilium are additional uncertain locations (HPA: subcellular). These IF observations do not establish the expected chromogenic paraffin-section IHC pattern (HPA: subcellular; HPA: tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| HPA-listed positive cells show no staining. | The relevant cells may be absent from the section, or an IHC processing or detection step may have failed (standard IHC practice). | Confirm cell identity and assess a known-working tissue control; review retrieval, primary incubation and chromogen development (standard IHC practice). Treat HPA Medium staining as provisional because tissue IHC reliability is Uncertain (HPA: tissue IHC). |
| Nuclei dominate the signal. | This differs from the documented cytoplasmic location (UniProt Q9Y4K4: subcellular location; HPA: tissue IHC). | Check whether nuclear colour persists in a no-primary control, then reassess antibody conditions and compartment scoring (standard IHC practice). Do not score nuclear-only staining as the expected MAP4K5 pattern (UniProt Q9Y4K4: cytoplasm). |
| Cells reported as HPA-negative stain strongly. | Cross-reactivity or endogenous detection activity can produce cell-specific colour (standard IHC practice); HPA lists adipocytes and cardiomyocytes as Not detected (HPA: tissue IHC). | Compare a no-primary control, review detection blocking and check staining in a listed medium-staining cell population (standard IHC practice; HPA: tissue IHC). A single HPA-negative result cannot validate specificity because HPA reliability is Uncertain (HPA: tissue IHC). |
| Background colour obscures cell boundaries. | Nonspecific antibody binding or endogenous detection activity may contribute (standard IHC practice). | Inspect no-primary controls, revisit blocking and washing, and adjust primary antibody concentration using the antibody's IHC guidance if available (standard IHC practice). Score only where cytoplasmic signal is distinguishable from background (UniProt Q9Y4K4: cytoplasm; standard IHC practice). |
| Staining varies across a section or between runs. | Uneven reagent coverage, retrieval or development can alter chromogenic signal (standard IHC practice); no MAP4K5-specific fixation sensitivity is supplied (UniProt Q9Y4K4; HPA: tissue IHC). | Check section coverage and run controls, then compare like-for-like regions and cell populations (standard IHC practice). Avoid attributing the variation to a MAP4K5-specific fixation effect without direct evidence. |
| A bright membrane rim is the only positive feature. | HPA's additional plasma-membrane ICC-IF localization is Uncertain; the supported ICC-IF location is cytosol (HPA: subcellular). | Inspect cytoplasmic staining and controls before scoring the IHC result (UniProt Q9Y4K4: cytoplasm; standard IHC practice). Record a membrane-only result as discordant with the expected tissue IHC pattern (HPA: tissue IHC). |
Experiment evidence
IHC & IF images showing MAP4K5 staining
A10186-1 · IHCIHC analysis of MAP4K5 using anti-MAP4K5 antibody (A10186-1). MAP4K5 was detected in paraffin-embedded section of human ovarian cancer tissu
A10186-1 · IFIF analysis of MAP4K5 using anti-MAP4K5 antibody (A10186-1). MAP4K5 was detected in immunocytochemical section of A431 cells. Enzyme antigen
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000012983-MAP4K5/tissue/cerebral+cortex#imid_9076588
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000012983-MAP4K5/tissue/colon#imid_9076514
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000012983-MAP4K5/tissue/liver#imid_9076499
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000012983-MAP4K5/tissue/kidney#imid_9076508
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA036696; green = MAP4K5, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA036696; green = MAP4K5, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MAP4K5 IHC & IF
🧪Run cerebellum first and look for staining in Purkinje cells (HPA: Medium in cerebellar Purkinje cells); use adipose tissue as the negative comparator and assess adipocytes (HPA: Not detected in adipocytes). On the cerebellar slide, neighboring cells without visible signal should remain at background, but the supplied HPA rows do not establish a specific internal negative cell type.
Positive control tissue: Cerebellum (Purkinje cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAP4K5 in A-431, U2OS, Rh30, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a concentration-matched rabbit IgG isotype control matched to the primary antibody’s clonality, and a MAP4K5 knockout sample or validated peptide-block control (caption: rabbit anti-MAP4K5 antibody; standard IHC controls). Check cerebellar sections for endogenous peroxidase and biotin background before interpreting DAB signal because the reported detection uses a streptavidin–biotin complex with DAB (selected-SKU caption: SABC/DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU caption: fixative unreported). That caption reports heat retrieval in EDTA at pH 8.0, so use it as a starting condition while checking retrieval dependence experimentally (selected-SKU caption: EDTA retrieval); the supplied evidence does not establish whether frozen sections or IF are easier. For cerebellum, verify that apparent Purkinje-cell staining exceeds endogenous peroxidase or biotin background with the stated chromogenic system (HPA: Medium in Purkinje cells; selected-SKU caption: SABC/DAB).
HPA tissue IHC evidence for MAP4K5
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Purkinje cells | Medium | Protein (IHC) | HPA → |
| Colon | Endothelial cells | Medium | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Medium | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Medium | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MAP4K5 IHC Tips
Troubleshoot MAP4K5 staining by checking retrieval, cytoplasmic localisation, cell type and controls before comparing chromogenic IHC results across sections.
What retrieval should I use when MAP4K5 staining is weak in paraffin sections?
Start with heat-mediated retrieval in EDTA, pH 8.0, for paraffin sections stained with A10186-1 (datasheet A10186-1). The reported ovarian cancer section used this retrieval before overnight incubation with 2 µg/mL primary antibody at 4°C (datasheet A10186-1). If staining remains weak, compare a shorter and longer heating exposure on adjacent sections while holding detection conditions constant, because excessive retrieval can damage morphology (standard IHC practice). Include a no-primary control and evaluate signal in intact cells rather than torn or detached tissue; the published caption does not establish an optimal heating duration (datasheet A10186-1; standard IHC practice).
Could fixation explain weak or uneven MAP4K5 staining?
Target-specific fixation sensitivity for MAP4K5 is unknown, and the A10186-1 paraffin-section caption does not state a fixative (datasheet A10186-1). Record the fixative, fixation interval and processing history for every section before comparing stain intensity across specimens (standard IHC practice). If a newly processed specimen stains poorly, compare it with a previously successful section using the same EDTA, pH 8.0, retrieval and detection workflow (datasheet A10186-1; standard IHC practice). Examine morphology and staining across the section, since uneven processing can complicate interpretation; HPA tissue patterns and MAP4K5 annotations cannot establish a fixation effect (standard IHC practice; HPA tissue IHC; UniProt Q9Y4K4).
Where should convincing MAP4K5 staining appear in tissue?
Assess cytoplasmic staining first: MAP4K5 is annotated as cytoplasmic, and cytosolic localisation has subcellular support (UniProt Q9Y4K4; HPA subcellular). HPA tissue IHC describes cytoplasmic expression in a subset of tissues, mainly smooth muscle, but assigns its tissue staining Uncertain reliability because antibody staining and RNA expression show low consistency (HPA tissue IHC). In a positive section, check that DAB lies within recognisable cell boundaries and persists across intact tissue, rather than only at cut edges (standard IHC practice). Treat isolated membrane or ciliary staining cautiously because those additional localisations are uncertain in the subcellular record (HPA subcellular).
How should epitope location affect interpretation of MAP4K5 IHC?
MAP4K5 is annotated as one 846-aa chain with no signal peptide or transmembrane segment, so assess staining against its expected intracellular distribution (UniProt Q9Y4K4). The record lists a kinase domain at residues 20–277, a CNH domain at 506–819, and phosphoserines at 335 and 433 (UniProt Q9Y4K4). It lists 0 isoforms, but the supplied caption does not identify A10186-1's epitope, so domain-specific or phosphorylation-specific recognition cannot be assigned (UniProt Q9Y4K4; datasheet A10186-1). If two antibodies disagree, compare their documented epitopes and staining controls before interpreting the difference as MAP4K5 biology (standard IHC practice).
How can I use IF to investigate an ambiguous MAP4K5 IHC pattern?
Use IF as a complementary localisation check, comparing MAP4K5 with a marker for the cell population implicated by the IHC pattern, such as smooth muscle (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores and inspect an unstained tissue section for autofluorescence before interpreting apparent colocalisation (standard IF practice). Because MAP4K5 lacks a transmembrane segment and its supported location is cytosolic, use permeabilisation compatible with access to intracellular epitopes, then verify morphology and marker retention (UniProt Q9Y4K4; HPA subcellular; standard IF practice). Keep IF interpretation separate from the A10186-1 paraffin-section result, whose caption reports chromogenic detection and does not establish an IF protocol (datasheet A10186-1).
How do I reduce diffuse brown background without losing MAP4K5 signal?
First inspect a no-primary control and compare background in tissue compartments with the proposed cellular signal (standard IHC practice). The A10186-1 paraffin-section workflow used 10% goat serum blocking, 2 µg/mL primary antibody overnight at 4°C, and biotinylated secondary detection with DAB (datasheet A10186-1). If diffuse staining persists, titrate primary antibody, strengthen appropriate washing, and include a peroxidase block for the chromogenic workflow while keeping retrieval constant (standard IHC practice). Consider endogenous biotin background when interpreting avidin-biotin detection, and require staining to match plausible cytoplasmic cell outlines rather than diffuse tissue-wide colour (datasheet A10186-1; UniProt Q9Y4K4; standard IHC practice).
How should I score MAP4K5 IHC across heterogeneous tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and tissue area before scoring, then use the same exposure to DAB development and counterstaining criteria across sections (standard IHC practice). For cellular staining, report the percentage of positive eligible cells and an H-score when intensity categories can be applied consistently; for sparse cells, report positive cells per mm² of viable tissue (standard IHC practice). Normalise counts to the number of eligible cells or viable area, and exclude folds, necrosis and detached edges using prespecified rules (standard IHC practice). Report compartment and cell type alongside scores because HPA tissue IHC has Uncertain reliability and describes a subset-specific cytoplasmic pattern (HPA tissue IHC).
What distinguishes true MAP4K5 staining from artefact in my section?
Prioritise reproducible cytoplasmic DAB within intact cells, consistent with MAP4K5's annotated cytoplasmic location and supported cytosolic localisation (UniProt Q9Y4K4; HPA subcellular). Compare the stained cell population with tissue architecture; HPA reports medium staining in ovarian follicle cells, among other populations, but rates its tissue IHC reliability Uncertain (HPA tissue IHC). Discount signal limited to section edges, necrotic material or compartments highlighted equally by a no-primary control, and check whether endogenous enzyme activity contributes to DAB colour (standard IHC practice). Treat exclusive strong nuclear, membrane or ciliary staining as requiring independent validation before assigning it to MAP4K5 (UniProt Q9Y4K4; HPA subcellular; standard IHC practice).
Boster reagents
Best MAP4K5 / Mitogen-activated protein kinase kinase kinase kinase 5 IHC Antibodies
The catalog antibody has IHC data from human paraffin-embedded ovarian cancer tissue and IF/ICC data from A431 cells (IHC and IF image captions).
Real IHC data
Anti-MAP4K5 Antibody ®
Cat # A10186-1
A10186-1 was demonstrated on a human paraffin-embedded ovarian cancer section by chromogenic IHC (IHC image caption; catalog reactivity: Human). A10186-1 was also demonstrated by IF/ICC on A431 cells (IF image caption; catalog applications: IF, ICC).
Which to pick: Choose A10186-1 for paraffin-section IHC: its image caption documents heat retrieval in EDTA at pH 8.0 and DAB detection (IHC image caption). The same SKU is listed for IF/ICC and has an A431-cell IF image; its host is rabbit, while clonality is unreported. No cross-species choice is supported because reactivity is listed only for human, and the paraffin-section caption does not report the fixative (catalog reactivity: Human; IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9Y4K4 (M4K5_HUMAN, Mitogen-activated protein kinase kinase kinase kinase 5).
- Human Protein Atlas. MAP4K5 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. MAP4K5 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the plasma membrane and primary cilium..
- Human Protein Atlas. MAP4K5 antibody validation summary (2 antibodies).
- Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. PloS one 2016 — PMC4811546.
- Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL(pro) substrate degradome. Cell reports 2021 — PMC8501228.
- PubMed PMID:9038372 — UniProt-cited evidence.
- PubMed PMID:12508121 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MAP4K5 (Mitogen-activated protein kinase kinase kinase kinase 5). Expected localisation Cytoplasmic staining in a subset of tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A10186-1). Validated IHC antibody: A10186-1 at 2μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Purkinje cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human ovarian cancer tissue; fixative not specified (datasheet A10186-1); 2. Fixation: Image fixative and duration unreported (datasheet A10186-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A10186-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A10186-1); 8. Primary antibody: Rabbit anti-MAP4K5, 2μg/ml (datasheet A10186-1); 9. Primary incubation: Overnight at 4 °C (datasheet A10186-1). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Tissue staining has uncertain reliability and low RNA concordance (HPA tissue IHC); Isoform / epitope: No listed isoforms; one unprocessed chain (UniProt); Regulation: Higher in ovary, testis and prostate (UniProt). Evidence: UniProt Q9Y4K4, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the plasma…, Datasheet A10186-1, PMC4811546. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MAP4K5/immunohistochemistry-ihc-guide.